Approval Expanded for Venetoclax in Chronic Lymphocytic Leukemia

FDA expanded the approval of venetoclax (Venclexta) for people with chronic lymphocytic leukemia (CLL) to include those whose cancer has progressed after previous treatment, regardless of whether their cancer cells have the deletion 17p gene alteration.

Cancer Currents: An NCI Cancer Research Blog